Core Viewpoint - The recent announcement by Shenzhen Kangtai Biological Products Co., Ltd. regarding the termination of the concerted action agreement between its actual controllers, Du Weimin and Yuan Liping, has reignited concerns over the company's control stability and potential shareholder dilution following their high-profile divorce that split a market value of 23.5 billion yuan [3][5]. Group 1: Shareholder Dynamics - The termination of the concerted action agreement has resulted in Du Weimin's voting rights decreasing from 46.62% to 25.50%, while Yuan Liping now holds 17.07% [5]. - Yuan Liping has committed not to seek control of the company post-termination, aiming to alleviate market concerns regarding control instability [5]. - Since the divorce in 2020, Yuan Liping has reduced her holdings significantly, cashing out nearly 3 billion yuan, raising fears of further dilution of shares following the termination of the agreement [6]. Group 2: Operational Challenges - Kangtai Biological's core business includes the research, production, and sales of human vaccines, with key products such as the 13-valent pneumococcal polysaccharide conjugate vaccine and others [7]. - The company has faced significant operational challenges, including the resignation of a vice president and the termination of a joint venture with AstraZeneca, which was intended to invest approximately 2.76 billion yuan [8][10]. - The decision to terminate the joint venture was influenced by a rapidly changing market environment and increased risks associated with new investments in the vaccine industry [10]. Group 3: Financial Performance - Kangtai Biological's financial outlook is concerning, with a projected net profit for 2025 expected to decline by 63.80% to 75.70%, amounting to between 49 million and 73 million yuan [10]. - The company's performance has been volatile, with net profits peaking at 1.263 billion yuan in 2021, followed by a loss of 133 million yuan in 2022, and a recovery in 2023 and 2024, only to face another significant decline in 2025 [11]. - As of February 11, 2026, the company's stock price has plummeted nearly 90% from 146 yuan per share at the time of the divorce, reflecting a substantial decrease in valuation [11].

Core Insights - The flu positive rate in China has reached nearly 45%, indicating a significant rise in flu cases, with some provinces experiencing high epidemic levels [1] - Investors are closely monitoring the supply and sales of flu medications and vaccines from listed pharmaceutical companies, which are actively preparing to meet public health needs [1] Group 1: Drug and Vaccine Supply - Multiple listed companies have reported sufficient reserves of flu medications and vaccines, ensuring stable supply capabilities [2] - Renhe Pharmaceutical has initiated a priority supply mechanism for Oseltamivir, while Dajia Weikang has adjusted production capacity based on market demand [2] - The entire supply chain, including raw material suppliers like Rhine Bio, is collaborating to ensure a robust response to market needs [2] Group 2: Vaccine Development - Companies are focusing on flu vaccines as a key area for development, with several achieving significant progress by 2025 [3] - Zhejiang Tianyuan Biopharmaceutical's quadrivalent flu vaccine "Yufening" has been approved for sale, alongside its trivalent vaccine "Yuganning" [3] - Baike Bio has innovated with a freeze-dried nasal spray flu vaccine, which has been upgraded to a liquid form for easier administration [3] Group 3: Treatment Options - Companies are building a diverse matrix of flu medications to address various symptoms and treatment needs [5] - Zhongsheng Pharmaceutical is advancing the commercialization of Anladiwei tablets for treating uncomplicated influenza, while Jichuan Pharmaceutical is developing a novel flu treatment [5] - Oseltamivir remains a commonly used antiviral, with multiple companies like Renfu Pharmaceutical and Dajia Weikang actively involved in its production [5][6] Group 4: Symptomatic Relief - Several companies are providing symptomatic treatments for flu, including Lisheng Pharmaceutical's Acetaminophen and various products from Zhenbaodao for symptom relief [6] - Companies like Foci Pharmaceutical produce a range of cold and flu medications, ensuring comprehensive treatment options for patients [6]

Core Viewpoint - The company has developed a lyophilized nasal spray influenza vaccine suitable for individuals aged 3 to 17, which simulates natural infection and induces both systemic and local mucosal immunity with a validity period of 10 months [1] Group 1: Product Details - The lyophilized nasal spray influenza vaccine is the only nasal spray live attenuated influenza vaccine in China, significantly improving vaccination compliance among recipients [1] - The liquid nasal spray influenza vaccine received production approval in August 2025, representing an upgrade from the lyophilized form, eliminating the need for reconstitution during use [1] Group 2: Regulatory and Global Context - The lyophilized nasal spray influenza vaccine is part of the World Health Organization's (WHO) Global Action Plan for Influenza Vaccines (GAP) [1]